News | Cardiac Diagnostics | January 25, 2018

Five Health Indicators Are Enough to Predict Cardiovascular Risk, Mount Sinai Researchers Report

Fuster-BEWAT score could be an affordable, painless alternative in developing countries without access to laboratory data

Five Health Indicators Are Enough to Predict Cardiovascular Risk, Mount Sinai Researchers Report

January 25, 2018 – In a large population study that was the first of its kind, researchers found that a simple tool not requiring laboratory tests, the Fuster-BEWAT score, is as effective as the American Heart Association-recommended ICHS (Ideal Cardiovascular Health Index), which includes blood analysis of cholesterol and glucose.

The Fuster-BEWAT score evaluates five health indicators: blood pressure, physical activity, body-mass index, fruit and vegetable intake, and smoking status, and does not require a blood test. These results demonstrate the usefulness of the Fuster-BEWAT score as an index of subclinical atherosclerosis.

The study, carried out at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) in Madrid, Spain, demonstrates that the Fuster-BEWAT score effectively predicts the presence and extent of subclinical (asymptomatic) atherosclerosis in healthy middle-aged individuals with no known history of cardiovascular disease. Moreover, Fuster-BEWAT predictions are as accurate as those obtained with the widely used ICHS.

Previous studies, like the PURE study, coordinated by Salim Yusuf, MD and recently published in The Lancet, had already indicated that blood analysis can sometimes be omitted from cardiovascular risk calculations, a particular advantage in regions with limited health care resources.

Researchers from the Icahn School of Medicine at Mount Sinai, CNIC, and other institutions studied 3,983 middle-aged participants without prior cardiovascular disease who were employees of the Banco de Santander in Madrid. This is an ongoing observational prospective cohort study in which participants are being followed for 10 years. The results demonstrate the usefulness of the Fuster-BEWAT score for evaluating cardiovascular risk in situations where it is not possible to obtain blood samples.

“The Fuster-BEWAT score may be particularly relevant in low-resource areas, such as developing countries, where the burden of cardiovascular disease is growing faster than in the rest of the world,” said the study’s corresponding author, Valentin Fuster, M.D., Ph.D., director of Mount Sinai Heart and physician-in-chief of The Mount Sinai Hospital. “The Fuster-BEWAT score is an easy, painless, inexpensive tool that could be implemented in resource-constrained health care settings to identify individuals with a high likelihood of subclinical atherosclerosis at whom preventative management strategies can be directed.”

The study is part of an international initiative that is being conducted through partnerships with the National Center for Cardiovascular Research in Spain, the Icahn School of Medicine at Mount Sinai and the Framingham Heart Study.

Follow up studies in the research cohort will investigate if participants showing ideal ICHS and Fuster-BEWAT metrics have less progression of subclinical atherosclerosis and lower incidence of clinical events over time.

For more information: www.mountsinai.org

Related Content

Late Dinner and No Breakfast Worsens Outcomes After Heart Attack
News | Cardiac Diagnostics | May 23, 2019
People who skip breakfast and eat dinner near bedtime have worse outcomes after a heart attack, according to research...
HRS Releases New Expert Consensus Statement on Arrhythmogenic Cardiomyopathy
News | Cardiac Diagnostics | May 14, 2019
The Heart Rhythm Society (HRS) released a first-of-its-kind consensus statement with guidance on the evaluation and...
New Best Practices Help Manage Heart Attack Patients Without Significant Signs
News | Cardiac Diagnostics | April 15, 2019
For the first time in the United States, doctors with the American Heart Association (AHA) have outlined best practices...
The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes.

The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes. 

Feature | Cardiac Diagnostics | March 22, 2019 | Linda C. Rogers, Ph.D.
Troponins are a family of proteins found in skeletal and heart (cardiac) muscle fibers that produce muscular contract
ACC/AHA Update Guidance for Preventing Heart Disease; Stroke
Feature | Cardiac Diagnostics | March 18, 2019
The choices we make every day can have a lasting effect on our heart and vascular health. Adopting a heart healthy...
AHA Statement Warns Hookah Smoking May Harm the Heart
News | Cardiac Diagnostics | March 08, 2019
Smoking tobacco in waterpipes, more commonly known as hookahs, results in inhaling toxic chemicals, often at levels...
PTSD Alone Does Not Increase Heart Disease Risk in Veterans
News | Cardiac Diagnostics | February 20, 2019
February 20, 2019 — Post-traumatic stress disorder (PTSD) by itself does not explain the...
Hormone Therapy May Increase Cardiovascular Risk During Gender Transition
News | Cardiac Diagnostics | February 18, 2019
Patients receiving hormone therapy as part of their gender-transition treatment had an elevated risk for cardiovascular...
IBM and Broad Institute Launch AI Initiative for Cardiovascular Disease Risk Prediction
News | Cardiac Diagnostics | February 15, 2019
IBM Watson Health and the Broad Institute of MIT and Harvard are launching a research partnership aimed at developing...
Overlay Init